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Of 40 ready-to-eat salads, 3 (7.5%) were positive for 
Clostridium difﬁ  cile by PCR. Two isolates were PCR ribo-
type 017 (toxin A–, B+), and 1 was PCR ribotype 001. Iso-
lates were susceptible to vancomycin and metronidazole but 
variably resistant to other antimicrobial drugs. Ready-to-eat 
salads may be potential sources for virulent C. difﬁ  cile.
O
ver the past decade, Clostridium difﬁ  cile infection has 
become a prominent cause of healthcare-associated in-
fection. Although C. difﬁ  cile has been thought of tradition-
ally as a predominantly nosocomial infection, the incidence 
of community-acquired cases has increased recently, as has 
the incidence of cases from other healthcare settings such 
as nursing homes (1). Notably, some evidence has shown 
that C. difﬁ  cile may be brought into the healthcare environ-
ment by asymptomatic carriers (2). The reported carriage 
rates of C. difﬁ  cile in healthy adults have varied from 0% 
to 3% in Europe to up to 15% in Japan (3). Little is known, 
however, about the prevalence of C. difﬁ  cile in the environ-
ment and how it may be transmitted to humans.
C. difﬁ  cile has been found in a variety of environments, 
including water, soil, animal feces, and foods (4,5); these 
ﬁ  ndings suggest that C. difﬁ  cile may be transmitted to hu-
mans through food, although no foodborne cases have been 
reported. Because ready-to-eat foods have been implicated 
in foodborne disease outbreaks associated with Salmonella 
species (6) and Escherichia coli O157 (7), we examined 
ready-to-eat salads for the presence of C. difﬁ  cile.
The Study
We tested 50-g samples from each of 40 packaged 
ready-to-eat salads purchased from 7 Glasgow supermar-
kets from May 1 through June 30, 2008, for the presence of 
C. difﬁ  cile spores. We essentially used the CDMN (C. dif-
ﬁ  cile, moxalactam, norﬂ  oxacin) agar method of Rodriguez-
Palacios et al. (4) but also used direct plating and enrich-
ment broth culture. The contents of the 40 salads generally 
differed, and any salads with the same contents carried 
different supermarket brands, which eliminated replicate 
sampling.
Isolates were identiﬁ  ed as toxigenic (having genes for 
toxins A and B) by PCR as previously described (8,9), and 
ribotypes were identiﬁ  ed by PCR (10). The MICs of 6 anti-
microbial drugs for these isolates were determined by using 
E-test strips (AB Biodisk, Solna, Sweden). The following 
MIC breakpoints were used to deﬁ  ne resistance to these 
drugs: metronidazole, >32 μg/mL; vancomycin, >16 μg/
mL; cefotaxime, 64 μg/mL; erythromycin, >8 μg/mL; mox-
iﬂ  oxacin, >8 μg/mL; and clindamycin, >8 μg/mL (Clinical 
and Laboratory Standards Institute, Wayne, PA, USA).
C. difﬁ  cile spores were detected in 3 (7.5%) of the 40 
salad samples after culturing in enrichment broth (Table 1). 
Thirty-ﬁ  ve (87.5%) of the salads were marked as import-
ed from European Union countries; the remaining 5 were 
from UK suppliers. The 3 contaminated salads were not of 
UK origin. The 3 isolates were found to be toxinogenic by 
PCR; 2 were PCR ribotype 017, and 1 was PCR ribotype 
001 (Table 1).
The MICs of 6 antimicrobial drugs for each isolate and 
the resistance proﬁ  le of each isolate are shown in Table 2. 
None of the isolates was resistant to vancomycin or metron-
idazole, and only the 001 isolate was resistant to moxiﬂ  oxacin 
and erythromycin. All 3 isolates were resistant or intermedi-
ately resistant to clindamycin and cefotaxime; breakpoints 
for these drugs were highest for the 001 isolate.
Isolates were obtained after being cultured in enrich-
ment broth and not by direct plating, which suggests that 
spore counts were low (<3.0 CFU/g). The infectious dose 
required to colonize the healthy human gut is, however, 
unknown. Isolates were of PCR ribotypes 001 (a common 
clinical isolate in Scotland [11]) and 017 (a common Eu-
ropean PCR ribotype containing isolates that are negative 
for toxin A and positive for toxin B  [12]). No isolate was 
resistant to vancomycin or metronidazole, which is in ac-
cord with ﬁ  ndings for other C. difﬁ  cile isolates found in 
Scotland (11), but recent studies have highlighted the emer-
gence of increased resistance to metronidazole among C. 
difﬁ  cile isolates in England (13).
In general, the PCR ribotype 001 isolate was more 
drug resistant than the 017 isolates; it was the only iso-
late resistant to moxiﬂ  oxacin and erythromycin and had 
the highest breakpoints to clindamycin and cefotaxime. 
In a 2005 study in which 271 C. difﬁ  cile isolates from 
the UK were examined, all were found to be resistant to 
cefotaxime (14).
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Table 1. PCR profile for toxins A and B and PCR ribotype of 
Clostridium difficile isolates, Scotland, 2008 
Sample no./description  Toxin A  Toxin B  PCR ribotype
13/baby leaf spinach  – + 017
24/organic mixed leaf salad  – + 017
35/organic lettuce  + + 001Conclusions 
The isolation of these PCR ribotypes from ready-to-eat 
salads is of concern and highlights the potential risk associ-
ated with consuming these salads, particularly since they 
are not cooked before being consumed. The consumption 
of these foods by vulnerable groups could possibly lead to 
C. difﬁ  cile colonization and an increase in the asymptomat-
ic C. difﬁ  cile carriage rate among humans, thus increasing 
the risk for C. difﬁ  cile transference within the healthcare 
environment (2). The presence of C. difﬁ  cile in ready-to-
eat salads could result from environmental contamination 
or transmission by food handlers. Further work is needed 
to investigate foods as a source of this pathogen and also to 
assess the role of soil and animals as its reservoirs.
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Table 2. Susceptibility of 3 Clostridium difficile isolates to 6 antimicrobial drugs, by source of isolate, Scotland, UK, 2008* 
Source of isolate 
Antimicrobial drug  Baby leaf spinach (MIC, μg/mL)  Organic mixed leaf salad (MIC, μg/mL)  Organic lettuce (MIC, μg/mL) 
Metronidazole S (0.125)  S (0.094)  S (0.75) 
Vancomycin  S (0.50)  S (0.38)  S (1.0) 
Moxifloxacin S (0.50)  S (0.75)  R (256) 
Clindamycin  I (4.0)  I (6.0)  R (8.0) 
Erythromycin   S (1.5)  S (0.75)  R (192) 
Cefotaxime I (48)  R (64)  R (256) 
*S, sensitive; R, resistant; I, intermediate. 
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